{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T08:12:35Z","timestamp":1777623155456,"version":"3.51.4"},"reference-count":56,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["3100A0-109981"],"award-info":[{"award-number":["3100A0-109981"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007393","name":"Association Fran\u00e7aise contre les Myopathies","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007393","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010767","name":"Stiftung f\u00fcr die Erforschung der Muskelkrankheiten","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007393","name":"Association Fran\u00e7aise contre les Myopathies","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007393","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007423","name":"Duchenne Parent Project","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007423","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajp.amjpathol.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Pathology"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/j.ajpath.2011.10.038","type":"journal-article","created":{"date-parts":[[2011,12,19]],"date-time":"2011-12-19T05:45:49Z","timestamp":1324273549000},"page":"749-762","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Urocortins Improve Dystrophic Skeletal Muscle Structure and Function through Both PKA- and Epac-Dependent Pathways"],"prefix":"10.1016","volume":"180","author":[{"given":"Julie","family":"Reutenauer-Patte","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois-Xavier","family":"Boittin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oph\u00e9lie","family":"Patthey-Vuadens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Urs T.","family":"Ruegg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier M.","family":"Dorchies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajpath.2011.10.038_bib1","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s10974-010-9206-9","article-title":"Regulation by scaffolding proteins of canonical transient receptor potential channels in striated muscle","volume":"30","author":"Sabourin","year":"2009","journal-title":"J Muscle Res Cell Motil"},{"key":"10.1016\/j.ajpath.2011.10.038_bib2","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/978-1-4020-6191-2_16","article-title":"Calcium misregulation and the pathogenesis of muscular dystrophy","volume":"45","author":"Hopf","year":"2007","journal-title":"Subcell Biochem"},{"key":"10.1016\/j.ajpath.2011.10.038_bib3","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.biocel.2010.11.005","article-title":"Duchenne muscular dystrophy: what causes the increased membrane permeability in skeletal muscle?","volume":"43","author":"Allen","year":"2011","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.ajpath.2011.10.038_bib4","doi-asserted-by":"crossref","first-page":"19023","DOI":"10.1073\/pnas.0906591106","article-title":"Calcium influx is sufficient to induce muscular dystrophy through a TRPC-dependent mechanism","volume":"106","author":"Millay","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ajpath.2011.10.038_bib5","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s00424-010-0856-7","article-title":"Toward the roles of store-operated Ca2+ entry in skeletal muscle","volume":"460","author":"Launikonis","year":"2010","journal-title":"Pfl\u00fcgers Arch Eur J Physiol"},{"key":"10.1016\/j.ajpath.2011.10.038_bib6","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1113\/jphysiol.2008.154997","article-title":"Orai, STIM1 and iPLA2\u03b2: a view from a different perspective","volume":"586","author":"Bolotina","year":"2008","journal-title":"J Physiol"},{"key":"10.1016\/j.ajpath.2011.10.038_bib7","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1242\/jcs.03184","article-title":"Ca2+-independent phospholipase A2 enhances store-operated Ca2+ entry in dystrophic skeletal muscle fibers","volume":"119","author":"Boittin","year":"2006","journal-title":"J Cell Sci"},{"key":"10.1016\/j.ajpath.2011.10.038_bib8","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0960-8966(94)00045-B","article-title":"Phospholipase A2 activity in dystrophinopathies","volume":"5","author":"Lindahl","year":"1995","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.ajpath.2011.10.038_bib9","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1161\/CIRCRESAHA.107.159053","article-title":"Role of Ca2+-independent phospholipase A2 and store-operated pathway in urocortin-induced vasodilatation of rat coronary artery","volume":"101","author":"Smani","year":"2007","journal-title":"Circ Res"},{"key":"10.1016\/j.ajpath.2011.10.038_bib10","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.bbrc.2009.11.070","article-title":"Phospholipase A2-derived lysophosphatidylcholine triggers Ca2+ entry in dystrophic skeletal muscle fibers","volume":"391","author":"Boittin","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.ajpath.2011.10.038_bib11","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2174\/138945008785132385","article-title":"Group VI phospholipases A2: homeostatic phospholipases with significant potential as targets for novel therapeutics","volume":"9","author":"Wilkins","year":"2008","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.ajpath.2011.10.038_bib12","first-page":"1","article-title":"Glucocorticoid Corticosteroids for Duchenne Muscular Dystrophy (Review)","author":"Manzur","year":"2008","journal-title":"The Cochrane Collaboration\/John Wiley & Sons, Ltd"},{"key":"10.1016\/j.ajpath.2011.10.038_bib13","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1111\/j.1476-5381.1995.tb15930.x","article-title":"Modulation by prednisolone of calcium handling in skeletal muscle cells","volume":"116","author":"Metzinger","year":"1995","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.ajpath.2011.10.038_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yfrne.2006.09.002","article-title":"Physiology, pharmacology, and therapeutic relevance of urocortins in mammals: ancient CRF paralogs","volume":"28","author":"Fekete","year":"2007","journal-title":"Front Neuroendocrinol"},{"key":"10.1016\/j.ajpath.2011.10.038_bib15","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0165-6147(02)01946-6","article-title":"The CRF peptide family and their receptors: yet more partners discovered","volume":"23","author":"Dautzenberg","year":"2002","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.ajpath.2011.10.038_bib16","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1073\/pnas.92.4.1108","article-title":"A sauvagine\/corticotropin-releasing factor receptor expressed in heart and skeletal muscle","volume":"92","author":"Kishimoto","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ajpath.2011.10.038_bib17","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1369\/jhc.4A6279.2004","article-title":"Corticotropin-releasing factor 2 receptor localization in skeletal muscle","volume":"52","author":"Samuelsson","year":"2004","journal-title":"J Histochem Cytochem"},{"key":"10.1016\/j.ajpath.2011.10.038_bib18","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/24884","article-title":"Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP","volume":"396","author":"de Rooij","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.ajpath.2011.10.038_bib19","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s00210-007-0246-7","article-title":"Epac: effectors and biological functions","volume":"377","author":"Roscioni","year":"2008","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.ajpath.2011.10.038_bib20","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1146\/annurev.pharmtox.010909.105714","article-title":"Epac: defining a new mechanism for cAMP action","volume":"50","author":"Gloerich","year":"2010","journal-title":"Ann Rev Pharmacol Toxicol"},{"key":"10.1016\/j.ajpath.2011.10.038_bib21","doi-asserted-by":"crossref","first-page":"E889","DOI":"10.1152\/ajpendo.00081.2003","article-title":"Activation of the CRF 2 receptor modulates skeletal muscle mass under physiological and pathological conditions","volume":"285","author":"Hinkle","year":"2003","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.ajpath.2011.10.038_bib22","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s10974-004-4088-3","article-title":"Corticotropin releasing factor 2 receptor agonists reduce the denervation-induced loss of rat skeletal muscle mass and force and increase non-atrophying skeletal muscle mass and force","volume":"25","author":"Hinkle","year":"2005","journal-title":"J Muscle Res Cell Motil"},{"key":"10.1016\/j.ajpath.2011.10.038_bib23","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1741-7015-5-18","article-title":"Corticotrophin releasing factor 2 receptor agonist treatment significantly slows disease progression in mdx mice","volume":"5","author":"Hinkle","year":"2007","journal-title":"BMC Med"},{"key":"10.1016\/j.ajpath.2011.10.038_bib24","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/mus.20820","article-title":"Effects of a CRF2R agonist and exercise on mdx and wildtype skeletal muscle","volume":"36","author":"Hall","year":"2007","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ajpath.2011.10.038_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nbd.2008.03.008","article-title":"Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophy","volume":"31","author":"Grounds","year":"2008","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.ajpath.2011.10.038_bib26","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.nmd.2009.05.003","volume":"19","author":"Nagaraju","year":"2009","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.ajpath.2011.10.038_bib27","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1093\/hmg\/5.8.1149","article-title":"Differential expression of dystrophin isoforms in strains of mdx mice with different mutations","volume":"5","author":"Im","year":"1996","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.ajpath.2011.10.038_bib28","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/bjp.2008.285","article-title":"Investigation of Debio 025, a cyclophilin inhibitor, in the dystrophic mdx mouse, a model for Duchenne muscular dystrophy","volume":"155","author":"Reutenauer","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.ajpath.2011.10.038_bib29","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S0960-8966(01)00273-5","article-title":"Creatine supplementation reduces skeletal muscle degeneration and enhances mitochondrial function in mdx mice","volume":"12","author":"Passaquin","year":"2002","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.ajpath.2011.10.038_bib30","doi-asserted-by":"crossref","first-page":"18248","DOI":"10.1074\/jbc.M000271200","volume":"275","author":"Atsumi","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ajpath.2011.10.038_bib31","doi-asserted-by":"crossref","first-page":"C616","DOI":"10.1152\/ajpcell.00425.2005","article-title":"Green tea extract and its major polyphenol (-)-epigallocatechin gallate improve muscle function in a mouse model for Duchenne muscular dystrophy","volume":"290","author":"Dorchies","year":"2006","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.ajpath.2011.10.038_bib32","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/ajcn\/75.4.749","article-title":"Green tea extract decreases muscle necrosis in mdx mice and protects against reactive oxygen species","volume":"75","author":"Buetler","year":"2002","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.ajpath.2011.10.038_bib33","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.biocel.2006.09.009","article-title":"Duchenne muscular dystrophy: focus on pharmaceutical and nutritional interventions","volume":"39","author":"Radley","year":"2007","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.ajpath.2011.10.038_bib34","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.nmd.2004.10.018","article-title":"The function of myostatin and strategies of myostatin blockade: new hope for therapies aimed at promoting growth of skeletal muscle","volume":"15","author":"Patel","year":"2005","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.ajpath.2011.10.038_bib35","first-page":"230","article-title":"Molecular mechanisms involving IGF-1 and myostatin to induce muscle hypertrophy as a therapeutic strategy for Duchenne muscular dystrophy","volume":"24","author":"Patel","year":"2005","journal-title":"Acta Myol"},{"key":"10.1016\/j.ajpath.2011.10.038_bib36","doi-asserted-by":"crossref","first-page":"H1992","DOI":"10.1152\/ajpheart.00602.2009","article-title":"Hypersensitivity of excitation: contraction coupling in dystrophic cardiomyocytes","volume":"297","author":"Ullrich","year":"2009","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.ajpath.2011.10.038_bib37","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1023\/A:1010384625954","article-title":"Mdx myotubes have normal excitability but show reduced contraction-relaxation dynamics","volume":"22","author":"Nicolas-Metral","year":"2001","journal-title":"J Muscle Res Cell Motil"},{"key":"10.1016\/j.ajpath.2011.10.038_bib38","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1097\/00001756-199812210-00009","article-title":"Potent suppressive effects of urocortin on splenic lymphocyte activity in rats","volume":"9","author":"Okamoto","year":"1998","journal-title":"Neuroreport"},{"key":"10.1016\/j.ajpath.2011.10.038_bib39","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1021\/bi701668v","article-title":"Structural and dynamic basis of phospholamban and sarcolipin inhibition of Ca2+-ATPase","volume":"47","author":"Traaseth","year":"2007","journal-title":"Biochemistry"},{"key":"10.1016\/j.ajpath.2011.10.038_bib40","doi-asserted-by":"crossref","first-page":"4191","DOI":"10.1073\/pnas.0409695102","article-title":"Convergent regulation of skeletal muscle Ca2+ channels by dystrophin, the actin cytoskeleton, and cAMP-dependent protein kinase","volume":"102","author":"Johnson","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ajpath.2011.10.038_bib41","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.nbd.2006.08.010","article-title":"Overactivity of exercise-sensitive cation channels and their impaired modulation by IGF-1 in mdx native muscle fibers: beneficial effect of pentoxifylline","volume":"24","author":"Rolland","year":"2006","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.ajpath.2011.10.038_bib42","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1038\/nature04147","article-title":"STIM1 is a Ca2+ sensor that activates CRAC channels and migrates from the Ca2+ store to the plasma membrane","volume":"437","author":"Zhang","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.ajpath.2011.10.038_bib43","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1124\/pr.58.3.7","article-title":"Inhibitors of brain phospholipase A2 activity: their neuropharmacological effects and therapeutic importance for the treatment of neurologic disorders","volume":"58","author":"Farooqui","year":"2006","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.ajpath.2011.10.038_bib44","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nrm3072","article-title":"CREB and the CRTC co-activators: sensors for hormonal and metabolic signals","volume":"12","author":"Altarejos","year":"2011","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.ajpath.2011.10.038_bib45","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nm1573","article-title":"SIK1 is a class II HDAC kinase that promotes survival of skeletal myocytes","volume":"13","author":"Berdeaux","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.ajpath.2011.10.038_bib46","doi-asserted-by":"crossref","first-page":"e24714","DOI":"10.1371\/journal.pone.0024714","article-title":"CREB is activated by muscle injury and promotes muscle regeneration","volume":"6","author":"Stewart","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ajpath.2011.10.038_bib47","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s10974-006-9076-3","article-title":"RyR isoforms and fibre type-specific expression of proteins controlling intracellular calcium concentration in skeletal muscles","volume":"27","author":"Reggiani","year":"2006","journal-title":"J Muscle Res Cell Motil"},{"key":"10.1016\/j.ajpath.2011.10.038_bib48","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00424-009-0747-y","article-title":"Role of the cAMP-binding protein Epac in cardiovascular physiology and pathophysiology","volume":"459","author":"M\u00e9trich","year":"2010","journal-title":"Pfl\u00fcgers Arch"},{"key":"10.1016\/j.ajpath.2011.10.038_bib49","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.bcp.2008.08.033","article-title":"The powerful cardioprotective effects of urocortin and the corticotropin releasing hormone (CRH) family","volume":"77","author":"Davidson","year":"2009","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.ajpath.2011.10.038_bib50","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.yjmcc.2011.06.002","article-title":"Relevance of urocortins to cardiovascular disease","volume":"51","author":"Emeto","year":"2011","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.ajpath.2011.10.038_bib51","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.peptides.2004.12.013","article-title":"Sauvagine analogs selective for corticotropin releasing factor 2 receptor: effect of substitutions at positions 35 and 39 on CRF2R selectivity","volume":"26","author":"Mazur","year":"2005","journal-title":"Peptides"},{"key":"10.1016\/j.ajpath.2011.10.038_bib52","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1152\/japplphysiol.90985.2008","article-title":"Multiple pathological events in exercised dystrophic mdx mice are targeted by pentoxifylline: outcome of a large array of in vivo and ex vivo tests","volume":"106","author":"Burdi","year":"2009","journal-title":"J Appl Physiol"},{"key":"10.1016\/j.ajpath.2011.10.038_bib53","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/mus.22127","article-title":"Liquid formulation of pentoxifylline is a poorly tolerated treatment for Duchenne dystrophy","volume":"44","author":"Zimmerman","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ajpath.2011.10.038_bib54","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/sj.bjp.0706669","article-title":"Systemic administration of \u03b22-adrenoceptor agonists, formoterol and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses","volume":"147","author":"Ryall","year":"2006","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.ajpath.2011.10.038_bib55","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.nmd.2006.08.012","article-title":"Low dose formoterol administration improves muscle function in dystrophic mdx mice without increasing fatigue","volume":"17","author":"Harcourt","year":"2007","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.ajpath.2011.10.038_bib56","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1210\/me.2003-0054","article-title":"Glucocorticoids regulate the expression of the mouse urocortin II gene: a putative connection between the corticotropin-releasing factor receptor pathways","volume":"17","author":"Chen","year":"2003","journal-title":"Mol Endocrinol"}],"container-title":["The American Journal of Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002944011010613?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002944011010613?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T14:34:08Z","timestamp":1757601248000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002944011010613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S0002944011010613"],"URL":"https:\/\/doi.org\/10.1016\/j.ajpath.2011.10.038","relation":{},"ISSN":["0002-9440"],"issn-type":[{"value":"0002-9440","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Urocortins Improve Dystrophic Skeletal Muscle Structure and Function through Both PKA- and Epac-Dependent Pathways","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajpath.2011.10.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}